参考文献/References:
[1] Mooij CF,Cheetham TD,Verburg FA,et al.2022 European thyroid association guideline for the management of pediatric Graves' disease[J].Eur Thyroid J,2022,11(1):e210073.DOI:10.1530/ETJ-21-0073.
[2] Rodanaki M,Lodefalk M,Forssell K,et al.The incidence of childhood thyrotoxicosis is increasing in both girls and boys in Sweden[J].Horm Res Paediatr,2019,91(3):195-202.DOI:10.1159/000500265.
[3] Rivkees SA.63 years and 715 days to the "boxed warning":unmasking of the propylthiouracil problem[J].Int J Pediatr Endocrinol,2010,2010:658267.DOI:10.1155/2010/658267.
[4] Rivkees SA,Szarfman A.Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children[J].J Clin Endocrinol Metab,2010,95(7):3260-3267.DOI:10.1210/jc.2009-2546.
[5] Rivkees SA.Controversies in the management of Graves' disease in children[J].J Endocrinol Invest,2016,39(11):1247-1257.DOI:10.1007/s40618-016-0477-x.
[6] Duntas LH.Block-and-replace vs.titration antithyroid drug regimen for Graves' hyperthyroidism:two is not always better than one[J].J Endocrinol Invest,2021,44(6):1337-1339.DOI:10.1007/s40618-020-01431-1.
[7] Ross DS,Burch HB,Cooper DS,et al.2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J].Thyroid,2016,26(10):1343-1421.DOI:10.1089/thy.2016.0229.
[8] Vigone MC,Peroni E,Di Frenna M,et al."Block-and-replace" treatment in Graves' disease:experience in a cohort of pediatric patients[J].J Endocrinol Invest,2020,43(5):595-600.DOI:10.1007/s40618-019-01144-0.
[9] van Lieshout JM,Mooij CF,van Trotsenburg ASP,et al.Methimazole-induced remission rates in pediatric Graves' disease:a systematic review[J].Eur J Endocrinol,2021,185(2):219-229.DOI:10.1530/EJE-21-0077.
[10] Azizi F,Takyar M,Madreseh E,et al.Long-term methimazole therapy in juvenile Graves' disease:a randomized trial[J].Pediatrics,2019,143(5):e20183034.DOI:10.1542/peds.2018-3034.
[11] El Fassi D,Banga JP,Gilbert JA,et al.Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies[J].Clin Immunol,2009,130(3):252-258.DOI:10.1016/j.clim.2008.09.007.
[12] Kahaly GJ,Stan MN,Frommer L,et al.A novel anti-CD40 monoclonal antibody,Iscalimab,for control of Graves hyperthyroidism-a proof-of-concept trial[J].J Clin Endocrinol Metab,2020,105(3):dgz013.DOI:10.1210/clinem/dgz013.
[13] Cheetham TD,Cole M,Abinun M,et al.Adjuvant rituximab-exploratory trial in young people with Graves' disease[J].J Clin Endocrinol Metab,2022,107(3):743-754.DOI:10.1210/clinem/dgab763.
[14] Committee on Pharmaceutical Affairs,Japanese Society for Pediatric Endocrinology,and the Pediatric Thyroid Disease Committee,et al.Guidelines for the treatment of childhood-onset Graves' disease in Japan,2016[J].Clin Pediatr Endocrinol,2017,26(2):29-62.DOI:10.1297/cpe.26.29.
[15] Xing T,Hu Y,Wang B,et al.Role of oral calcium supplementation alone or with vitamin D in preventing post-thyroidectomy hypocalcaemia:a meta-analysis[J].Medicine(Baltimore),2019,98(8):e14455.DOI:10.1097/MD.0000000000014455.
[16] Cappelli C,Braga M,De Martino E,et al.Outcome of patients surgically treated for various forms of hyperthyroidism with differentiated thyroid cancer:experience at an endocrine center in Italy[J].Surg Today,2006,36(2):125-130.DOI:10.1007/s00595-005-3115-3.
[17] Kovatch KJ,Bauer AJ,Isaacoff EJ,et al.Pediatric thyroid carcinoma in patients with Graves' disease:the role of ultrasound in selecting patients for definitive therapy[J].Horm Res Paediatr,2015.DOI:10.1159/000381185.
相似文献/References:
[1]陈晓铭 胡卓清 李潍 刘美莲 吴美芬 方烁 武革.CD40-1C/T多态性（rs1883832）与粤西汉族人Graves病的关系[J].国际内分泌代谢杂志,2015,(01):11.[doi:10.3760/cma.j.issn.1673-4157.2015.01.003]
Chen Xiaoming,Hu Zhuoqing,Li Wei,et al.Relationship between CD40-1C/T polymorphism（rs1883832）and Graves′ disease of Han population in western region of Guangdong province[J].International Journal of Endocrinology and Metabolism,2015,(05):11.[doi:10.3760/cma.j.issn.1673-4157.2015.01.003]
[2]刘媛 刘超.1型糖尿病青少年儿童心理行为问题研究进展[J].国际内分泌代谢杂志,2015,(01):63.[doi:10.3760/cma.j.issn.1673-4157.2015.01.016]
Liu Yuan,Liu Chao..Psychological problems in adolescents and children with type 1 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(05):63.[doi:10.3760/cma.j.issn.1673-4157.2015.01.016]
[3]赵永强,田德增,魏晓华,等.不同治疗方法对Graves病患者外周血淋巴细胞亚群的影响[J].国际内分泌代谢杂志,2015,(04):234.[doi:10.3760/cma.j.issn.1673-4157.2015.04.005]
Zhao Yongqiang*,Tian Dezeng,Wei Xiaohua,et al.Effects of different therapeutic methods on peripheral blood lymphocyte subgroups in patients with Graves' disease[J].International Journal of Endocrinology and Metabolism,2015,(05):234.[doi:10.3760/cma.j.issn.1673-4157.2015.04.005]
[4]瞿茹怡,李圣贤,陆咏,等.2q33区基因多态性与Graves病发病风险的研究[J].国际内分泌代谢杂志,2014,(02):77.[doi:10.3760/cma.j.issn.1673-4157.2014.02.002]
Qu Ruyi*,Li Shengxian,Lu Yong,et al.Association between 2q33 gene polymorphism and Graves' disease[J].International Journal of Endocrinology and Metabolism,2014,(05):77.[doi:10.3760/cma.j.issn.1673-4157.2014.02.002]
[5]朱萍,卫红艳,王坤玲,等.Graves病甲状腺功能亢进症性肝损害的
相关因素分析[J].国际内分泌代谢杂志,2017,37(03):164.[doi:10.3760/cma.j.issn.1673-4157.2017.03.005]
Zhu Ping,Wei Hongyan,Wang Kunling,et al.Related factors of hyperthyroidism-related liver dysfunction in Graves' disease[J].International Journal of Endocrinology and Metabolism,2017,37(05):164.[doi:10.3760/cma.j.issn.1673-4157.2017.03.005]
[6]马金刚 魏红丽 尚恒.Graves病患者外周血T细胞亚群与甲状腺
功能及甲状腺自身抗体间的相关性分析[J].国际内分泌代谢杂志,2020,40(01):21.[doi:10.3760/cma.j.issn.1673-4157.2020.01.005]
Ma Jingang,Wei Hongli,Shang Heng.Correlation between peripheral blood T cell subsets and thyroid function and thyroid autoantibodies in patients with Graves' disease[J].International Journal of Endocrinology and Metabolism,2020,40(05):21.[doi:10.3760/cma.j.issn.1673-4157.2020.01.005]
[7]陈莹 倪文婧 陈国芳 徐书杭.基于复发危险因素探讨Graves病治疗的新策略[J].国际内分泌代谢杂志,2022,42(04):260.[doi:10.3760/cma.j.cn121383-20210412-04031]
Chen Ying,Ni Wenjing,Chen Guofang,et al.New strategies for the treatment of Graves' disease based on risk factors of relapse[J].International Journal of Endocrinology and Metabolism,2022,42(05):260.[doi:10.3760/cma.j.cn121383-20210412-04031]